Thursday, 24 November – Friday 25 November 2016Brisbane Convention and Exhibition Centre

Co-ordinated by Professor Ken O’Byrne

Brisbane Cancer Conference

CONFERENCE HANDBOOK

At the home of the world’s first cancer vaccineTRANSLATIONAL RESEARCH INSTITUTE

AUSTRALIA

Brisbane Cancer Conference | November 24 – 25, 2016

Conference Sponsors

PLATINUM SPONSOR

GOLD SPONSOR

SILVER SPONSORS

Brisbane Convention and Exhibition Centre

Conference Sponsors

BRONZE SPONSORS

DONATIONS

Found from websiterecreate PMS

Brisbane Cancer Conference | November 24 – 25, 2016

11th November 2016

Dear Colleagues,

Welcome to the 3rd Brisbane Cancer Conference. With the establishment of the Brisbane Diamantina Health Partners, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant disease.

On Thursday 24th November the meeting will start with Breast Cancer, Prostate Cancer and Immuno-Oncology symposia running from 8am – 12pm, supported by educational grants from Roche, Janssen and Astrazeneca respectively. There will be an educational symposium supported by MSD at lunch-time followed by plenary lectures from 2pm – 4pm and subsequently workshops running from 4:30pm – 6:30pm.

The symposium gala dinner will be held on Thursday evening offering the opportunity to socialise with colleagues particularly from other institutions in the city and from Queensland.

The all-day meeting on 25th November will include plenary lectures followed by workshops in the morning and afternoon. A key session will be lectures by Brisbane oncology researchers that have contributed to global advances in our understanding of the epidemiology, molecular biology and treatment of malignant disease.

We have over 700 people already registered for the 3rd meeting this year demonstrating the need and value of the annual Brisbane Cancer Conference.

This conference is made possible through the support of the PA Research Foundation, Cancer Council Queensland, Brisbane Diamantina Health Partners, our sponsors and the time and effort of the chairs who put the workshops together. A special thanks also to Therese, Irene, Areti, Anita, Diane and all of the other volunteers who helped with the conference.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,

Professor Ken O’Byrne

brisbane diamantina health partners

Brisbane Convention and Exhibition Centre

Conference Program

Thursday 24 November 2016

8:00am–12pm Breast Research Conference supported by an Educational Grant from Roche–Genentech

Boulevard Room Hosted by Prof Rik Thompson

8:00am TRPV calcium permeable ion channels and breast cancer – Greg Monteith

8:20am DNA repair mutations in breast cancer – Eloise Dray

8:40am Improved efficacy of neoadjuvant compared to adjuvantimmunotherapy to eradicate metastatic disease – Jing Liu

9:00am Breast cancer immunotherapy: Present challenges and future perspectives – Riccardo Dolcetti

9:20am RANK Ligand as a target for breast cancer prevention in BRCA1–mutation carriers – Bill Dougall

9:40am Reversing resistance to monoclonal antibody therapy in HER2 positive and triple negative breast cancers – Fiona Simpson

10:00am Morning tea

10:30am Round table discussion

8:00am–12pm Prostate Cancer Symposium supported by an Educational Grant from Janssen

Room B1 and B2 Hosted by Prof Colleen Nelson

8:00am Session 1 – Cancer metabolism • Insulin in prostate cancer progression – Jenni Gunter• Adipokines and metabolic regulation of prostate cancer – Lisa Philp• Lipids fueling prostate cancer treatment resistance – Martin Sadowski• Targeting cancer metabolism, focus on amino acid transport – Jeff Holst

9:00am Session 2 – Tumour microenvironment • Targeting NRP1 in advanced prostate cancer – Marianna Volpert• Proteases in the tumour microenviroment activated by treatment – Thomas Kryza• Bioengineered 3D models for cancer – Dietmar Hutmacher• Can super castration be the answer? – Niall Corcoran

10:00am Morning tea

10:30am Session 3 – Metastases• Tumour plasticity and role of EMT – Brett Hollier• Genomic landscape of tumour metastases– Chris Hovens• Transcriptional read through; it is not always as it seems – Gregor Tevz

11:15am Session 4 – Computation biology • The forest of the trees: Genomic structure and variance in prostate cancer – Vanessa Hayes• Everything considered: Greating a full and complete transcriptome pipeline – Nenad Bartonicek• Computational approach to understanding gene networks – Ati Taherian Fard

Brisbane Cancer Conference | November 24 – 25, 2016

Conference Program

Thursday 24 November 20168:00am–12pm Immuno–Oncology supported by an Educational Grant from Astrazeneca

Room B3 Hosted by Prof Mark Smyth

8:00am Towards personalised medicine: Classification framework of immunotherapy and/or emerging targets for non–inflamed tumours – Mark Smyth

9:00am Immune therapy strategies in haematological malignancies – Maher Gandhi

9:30am Immune check point inhibitors – Beyond lung, melanoma & kidney cancer – Paul Mainwaring

10:00am Morning tea

10:30am CAR–T cells are serial killers – Paul Neeson

11:00am It’s not chemotherapy: Patient selection, managing toxicity & treatment duration – Kenneth O’Byrne

11:45am Discussion

12:30–1:30pm Educational Symposium supported by Merck Sharp and Dohme – Recent advances in immune–oncology

Room B1 and B2 Chair: Euan Walpole

12:30pm Biomarkers for immunotherapy – Sandra O’Toole

1:00pm Updates of the immune checkpoint revolution – Jeff Goh

12.00–12.30pm Lunch provided courtesy of Merck Sharp and Dohme

2:00–3:00pm Plenary lectures (1) – Improving patient outcomes in Queensland

Boulevard Auditorium Chairs: Robert Bowen, David Theile

2:00pm2:20pm 2:40pm

BDHP: What’s it all about? – David SiddleQGHA: An overview relevant to oncology – David BunkerQCCAT – Euan Walpole

3:00–4:00pm Plenary lectures (2)

Boulevard Auditorium Chair: Carolyn Mountford

3:00pm3:20pm3:40pm

Cancer biology and imaging – Sandro PorcedduThe microbiome in cancer – Gerald HoltmannQueensland pathology molecular diagnostics – Sunil Lakhani

4:00–4:30pm Afternoon tea

Brisbane Convention and Exhibition Centre

Conference Program

Thursday 24 November 20164:30–6:30pm Workshops

Room A1 Imaging Chairs: Liz Kenny, Stephen Rose

4:30pm4:43pm4:56pm5:09pm5:22pm5:35pm5:48pm6:01pm6:14pm6:27pm

• PET-MRI imaging of bone marrow – Ken Miles• Textural analysis – Samantha Worrall• PET-MRI imaging of glioma – Stephen Rose• Measuring interstitial pressure in solid tumours using DCE MRI – Nick Dowson• Theranostics in oncology – Manoj Bhatt• Molecular–guided PET-MRI imaging to target • Hypoxia in glioblastoma – Ben Chua• CXCR4 imaging in oral carcinoma – Sarju Vasani• Theranostics in glioma – Simon Puttick• Closing remarks – Liz Kenny

Room A2 Genomics Chair: John Pearson

4:30pm4:50pm5:10pm5:30pm5:50pm6:10pm

• GHQ: Changing practice to meet demand – Camron Ebzery• Whole–exome sequencing and cancer therapy – Matt Brown • Cancer gene panel testing – Michael Gattas• Direct targets of pSTAT5 in myeloproliferative neoplasms: New biology and biomarkers – Andrew Perkins• Colorectal cancer genomics – Vicki Whitehall• A plan for evaluating effectiveness of genomics in colorectal cancer: Can one test optimise patient management?

– Amanda Spurdle

Room B1 Clinical trials Chairs: Miriam Dwyer, Adam Stoneley

4:30pm4:35pm4:55pm5:15pm5:35pm5:55pm6:10pm6:20pm

• Introduction – Miriam Dwyer• Behind the scenes of a clinical trials unit and surviving an audit – Victoria Atkinson• Implications of national privacy principles for clinical trials – Lorinda Dressler• Medication safety in cancer therapy: The COSA best practice guidelines – Christine Carrington• Connecting patients with clinical trials – Rolland Suen• The importance of running a clinical trials unit as a business – Madelaine Chow• Using a CTMS to promote teamwork and reduce inefficiencies – Des Buckmaster• The Society for Clinical Research Sites – Adam Stoneley

Room B2 Commercialisation Chairs: Derek Richard, Mario Pennisi ‘It’s all in the translation’

4:30pm4.40pm4:50pm5:00pm5:10pm5:20pm5:30pm5:40pm5:50pm6:00pm6:10pm 6:20pm

• The biotech industry in Queensland – Mario Pennisi (Life Sciences, Queensland)• The role of universities in commercialisation – Prof Arun Sharma (QUT, DVCR)• The importance of a patent – Victor Argaet (Davies Collison Cave Pty Ltd)• Knowing the landscape – Amabel Tan (Thomson Reuters)• The role of venture capitol – Dr Michael Molinari (MRCF Investment Manager)• The R&D tax credit and investor incentives – May Bandi (Ernst & Young)• Increasing your value with a bio-report – Dimity Gransbury (Clinical Network Services)• Queensland Government: enabling the translation of research – Dr Geoff Garrett (Queensland Chief Scientist)• Support entrepreneurs in Brisbane – Councillor (Brisbane City Council)• Johnson & Johnson Innovation – Tamlyn O’Connor (Johnson & Johnson)• The Peplin story – Dr Jim Aylward (Oncolin)• Discussion facilitated by Mario Pennisi

Room B3 Palliative and supportive care research Chairs: Janet Hardy, John Haberecht

4:30pm4:50pm5:10pm5:30pm5:50pm 6:10pm

• Research with children who have died from cancer: Compass study – Leigh Donovan• Fertility discussion practices in AYA cancer – Natalie Bradford• Advance care planning in tertiary hospitals and the community – Leyton Miller • Palliative care doctors working in rural Australia – Alison Blight• Gastrograffin for constipation and bowel obstruction: What are we doing? – Phillip Good • Hummingbird House; taking flight – Kelly Oldham

7:00pm Gala Dinner

Brisbane Cancer Conference | November 24 – 25, 2016

Conference Program

Friday 25 November 2016 7:30am Registration desk opens

8:00–10:00am Plenary lectures

Boulevard Auditorium Chair: Shane Kelly

8:00am8:20am 8:40am9:00am9:20am9:40am

Evidence for preventability of skin cancer – Adele GreenRobotic surgery in prostate cancer – John Yaxley The role of genetics in improving patient reported outcomes – Kim Alexander Analgesics for cancer pain – Janet Hardy Adolescent and young adult cancer – Rik WalkerTele–Medicine and cancer research – Sabe Sabesan

10:00–10:30am Morning tea

10:30–12:00pm Workshops

Room A1 Hepatocellular cancer Chair: Katherine Stuart

10:30am10:55am11:20am11:55am

• Liver transplantation for HCC in the real world – J Fawcett• Imaging in HCC: It’s not black and white – Dr David Leggett• The rise and rise of HCC: An epidemiological view – Dr Paul Clark• Closing remarks

Room A2 Novel immunotherapies Chairs: Ian Frazer, Riccardo Dolcetti

10:30am10:35am

11:00am

11:25am

11:50am

• Opening remarks – Ian Frazer• Testing combination immunotherapies: Too many choices – how can we decide rationally what combinations to

test? – Fiona Simpson & James Wells• Picking target antigens: When is it feasible to personalise cancer immunotherapy? – Riccardo Dolcetti & Antonio

Pritchard• Assessing markers for likely efficacy/early assessment of actual efficacy of immunotherapy: What is possible?

– Maher Gandhi• Discussion

Room B1 Thoracic malignancies Chairs: Brett Hughes, Simon Bowler

10:30am10:45am11:00am11:15am11:30am11:45am

• Lung cancer screening in Queensland – Henry Marshall• Incorporating SABR into the management of early stage lung cancer – Ben Chua• Next–generation sequencing for NSCLC in Queensland – David Fairbairn• Phase I/II trial of dendritic cell vaccine and chemotherapy in malignant mesothelioma – Keith Horwood• Blood based biomarkers in lung cancer: Are exosomes the way of the future? – Andreas Moller• CDCA3, hSSB1 and SASH1: Novel prognostic and therapeutic targets in lung cancer – Mark Adams

Room B2 Brain tumours Chair: Mark Pinkham

10:30pm 10:42pm10:54pm

11:06pm11:18pm11:30pm11:42pm11:54pm

• Overview of the new WHO 2016 glioma classification – Thomas Robertson• Advanced MRI imaging for glioma – Jennie Roberts• A pilot image–based high throughput screen to identify DNA damage agents: From antimicrobial feed to

preclinical testing in malignant brain tumors – Yi Chieh Lim• Adoptive T cell therapy for GBM – Rajiv Khanna• Overview of clinical glioma trials in Brisbane – Kate Cuff• The Australian brain cancer survivorship study – Danette Langbecker• Potential benefits and feasibility of exercise during treatment for patients with brain tumours – Fiona Naumann• Discussion and closing remarks

Brisbane Convention and Exhibition Centre

Conference Program

Friday 25 November 2016Room B3 GU malignancies Chair: Ian Vela

10:30am10:45am11:00am11:15am11:30am11:45am

• PSMA expression in clear cell RCC and novel imaging technologies – Simon Wood• Novel radiation oncology trials in RCC – David Pryor• PCOR–QLD prostate cancer registry – Peter Heathcote • An integrated survivorship intervention for patients with prostate cancer – Patsy Yates• Combidex vs PSMA PET staging in high risk prostate cancer – Morgan Pokorny • Lu–PSMA theranostics in advanced prostate cancer – Paul Thomas

Boulevard Room Gynae–Oncology – John Hooper, Jim Coward, Pam Pollock Chair: Eva Baxter“Vignettes from the next generation of gynaecological cancer researchers”

10:30am 10:33am10:45am 10:57am 11:09am 11:21am11:33am 11:45am11:57am

• Opening remarks – Eva Baxter (3 min)• Pressing needs and emerging trends in treatment of gynaecological malignancies – Kathryn Middleton • Factors that influence survival after a diagnosis of endometrial cancer – Christina Nagle• PI3K inhibitors enhance the anti–tumour response of FGFR inhibitors in endometrial cancer – Leisl Packer• A novel approach to target ovarian cancer – Yaowu He• Cross–talk between tumours and normal cells via exosomes in ovarian cancer – Carlos Salomon• Aurora A is critical for survival in HPV–transformed cervical cancer – Sora Fallaha• Lymphoedema following gynaecological cancer: prevalence, incidence and risk – Megan Steele• Closing remarks – Jim Coward (3 min)

12:00–12:30pm Lunch

12:30–2pm Plenary lecturesLectures celebrating cancer research success in Brisbane

Boulevard Auditorium Chair: Stephen Ayre

12:30pm12:50pm1:10pm1:30pm 1:50pm

Advances in skin cancer screening – Peter SoyerTreatment and genomics in upper gastro–intestinal tract cancer – Andrew BarbourWhat genetics can tell us about the etiology of ‘sporadic’ breast cancer – Georgia Chenevix–TrenchStem cells in leukaemia – Steven LaneClinical trials App – Vladimir Andelkovic

2:00–2:30pm Afternoon tea

2:30–4:00pm Workshops

Room A1 Haematology Chair: Steve Lane

2:30pm2:45pm3:00pm3:15pm3:30pm3:45pm

• Hereditary haematologic malignancies – Helen Marfan • Recipient dendritic cells regulate graft vs host and graft vs leukaemia effects after BMT – Kate Markey• EphA3 in the AML niche – Chris Slape• Targeted NGS for the detection of MLL fusions in childhood leukaemia – Andrew Moore• Clinical deterioration and dying of patients with haematological cancer– Elise Button• Discussion

Room A2 Breast cancer Chair: Rik Thompson

2:30pm

2:43pm2:56pm3:09pm3:22pm

3:35pm

3:48pm

• Novel long noncoding RNAs, CUPID1 and CUPID2, mediate breast cancer risk at 11q13 by modulating response to DNA damage – Juliet French

• Turning pro–tumoural macrophages into effectors of anti–breast cancer therapy – Roberta Mazzieri• Current clinical trials options for advanced breast cancer in Queensland – Kathryn Middleton• Predicting treatment failure in luminal breast cancer – Cameron Snell• The nuclear receptor Nur77/NR4A1 regulates breast cancer tumour growth, metastasis and clinical outcome –

George Muscat• Exercise behaviour change in women after breast cancer: Results of the women’s wellness after cancer trial –

Amanda McGuire• Discussion

Brisbane Cancer Conference | November 24 – 25, 2016

Conference Program

Friday 25 November 2016Room B1 Melanoma and skin cancer Chairs: Peter Soyer, Nikolas Haass

2:30pm2:40pm2:50pm3:00pm

3:10pm3:20pm3:30pm3:40pm3:50pm

• Towards biomarkers of progression and prognosis – Lauren Aoude• Melanoma vascularisation: Endothelial progenitors to inform anti–angiogenic therapy – Prudence Donovan• Characterising the BRN2–MITF axis in melanoma cells: Flicking the chromatin switch to invasion – Aaron Smith• MITF regulates cell adhesion and subcompartment–specific distribution of differentially cycling melanoma cells

– Loredana Spoerri• Consequences of heterogeneous transcription factor expression in melanoma drug response – Glen Boyle• Histone methylation in stress induced drug tolerant cells – Heinz Hammerlindl• S–phase checkpoint–defective melanomas are selectively sensitive to CHK1 inhibitors – Zay Yar Oo• Targeting adenosine in BRAF–mutated melanoma reduces tumor growth and metastases – Arabella Young• Translating clinical science into practice – Victoria Atkinson

Room B2 Head and neck cancer Chairs: Jim Coward, Chris Perry

2:30pm 2:33pm 2:44pm2:55pm2:05pm2:17pm2:27pm2:37pm 2:47pm2:57pm

• Opening remarks • Novel approaches to HNSCC imaging – Trevor Watkins • Trans–oral surgery and robotics in H&N cancer – Neil de Zoysa• Improving the therapeutic ratio in radiotherapy – Ben Chua• Systemic therapy updates in HNSCC – Margie McGrath• ENHANCES trial: Survivorship care intervention for head and neck cancer – Jane Turner • De–escalating high dose Cisplatin in HNSCC – Geoff Peters• Dynamin inhibition in HNSCC – Fiona Simpson• Could precision medicine be tailor–made for metastatic head and neck cancers? – Arutha Kulasinghe• Closing remarks

Room B3 Small 3D cancer models workshop Chair: Laura Bray

2:30pm 2:35pm

3:15pm

3:35pm

• Overview of the agenda; goals for the day – Laura Bray• 3D Hydrogel manufacture

1. Investigating melanoma heterogeneity in real-time cell cycle imaging using a 3D using a tumourspheroid model – Sheena Daignault

2. Star PEG-heparin hydrogels for the study of cancer angiogenesis – Laura Bray3. 3D constructs to study cancer metastasis to bone – Ali Shokoomand4. A modular 3D cell culture platform – Daniela Loessner

• 3D Scaffold manufacture 1. 3D printed biomimetic nanocomposite model for breast cancer bone metastasis – Nathan Castro2. Melt electrospinning for 3D cancer models – Elena de Juan Pardo

• 3D Imaging and Analysis1. 3D imaging techniques – Anthony Davies2. The use of IMARIS software for quantitative analysis of 3D cellular constructs – Nathalie Bock3. AMIRA analysis of 3D vascular networks – Laura Bray

Boulevard Room Colorectal cancer Chairs: Vikram Jain, Barbara Leggett, Chris Gillespie

2:30pm2:45pm3:00pm3:15pm3:30pm3:45pm

• Radiology updates in Colorectal cancer – Sonja Gustafson • Maximally invasive techniques for rectal cancer – Craig Harris• Molecular genetics of colorectal cancer – Catherine Bond• Medical oncology updates for colorectal cancer – Matthew Burge• Financial toxicity in colorectal cancer patients – Louisa Gordon• Discussion – Time to get our act together workshop; opportunities and ideas for collaboration and research

4:00pm Cancer Research Funding, Queensland Chair: Frank GannonAdvance Queensland Program and Cancer Research – Christine Williams

4:50pm Closing remarks – Ken O’Byrne

Brisbane Convention and Exhibition Centre

Venue Floor Plans

Arbour LevelBCEC on Grey Street

Lower Level of BoulevardAuditorium

Speakers Presentation Centre

Lift

Backstage

ChangeRoom

GreenRoom

ArbourSpeakers Lounge

Lobby

Arbour Boardroom

Lift

Lift

Arbour Foyer

Lift

BarArbour LoungeA2

Lift

Retail Mezzanine A1

Arbour Level Rooms Theatre Classroom Banquet Cocktail Metres2

Arbour Lounge - - - 150 190

Meeting Room A1 50 30 20 60 70

Meeting Room A2 120 70 80 120 120

Arbour Speakers Presentation Centre - - - - 70

Arbour Boardroom - - 16 - 38

Grey StMerivale St

Glenelg St

Melbourne StMezzanine Level

Foyer Level Ground Level

Arbour Level

Boulevard Level

Plaza Level(Grey Street)

(Grey Street)

(Grey Street)

(Grey Street)

(Grey Street)

Sky Level(Grey Street)

Plaza Level(Merivale Street)

(Merivale Street)

(Merivale Street)

Concord Level

Important notes• Theatre and classroom capacities include staging, for speaker appropriate to the size of the room.• Banquet and cocktail capacities are the comfortable maximums for each room. Staging and/or dance floors have not been incorporated and will reduce these capacities.• Information accurate at time of printing.

more personal - more choice

31.7.2012 www.bcec.com.au

Boulevard LevelBCEC on Grey Street

BoulevardAuditorium

Boulevard Auditorium Foyer

BoulevardRoom

B1B2B3Lobby

Lift

Lift

Lift

Boulevard Room Foyer

Boulevard North Terrace

Boulevard Central TerraceRegistration

Bar

LoadingGreen Room

Bar

Boulevard Level Rooms Theatre Classroom Banquet Cocktail Metres2

Boulevard Auditorium 430 - - - -

Meeting Room B1 130 75 80 110 113

Meeting Room B2 130 75 80 110 113

Meeting Room B3 130 75 80 110 113

Meeting Room B1 & B2 270 160 180 240 231

Meeting Room B2 & B3 270 160 180 240 231

Meeting Rooms B1, B2 & B3 450 260 280 350 345

Boulevard Room 600 350 390 600 530

Grey StMerivale St

Glenelg St

Melbourne StMezzanine Level

Foyer Level Ground Level

Arbour Level

Boulevard Level

Plaza Level(Grey Street)

(Grey Street)

(Grey Street)

(Grey Street)

(Grey Street)

Sky Level(Grey Street)

Plaza Level(Merivale Street)

(Merivale Street)

(Merivale Street)

Concord Level

Important notes• Theatre and classroom capacities include staging, for speaker appropriate to the size of the room.• Banquet and cocktail capacities are the comfortable maximums for each room. Staging and/or dance floors have not been incorporated and will reduce these capacities.• Information accurate at time of printing.

more personal - more choice

31.7.2012 www.bcec.com.au

Boulevard Level

Arbour LevelBCEC on Grey Street

Lower Level of BoulevardAuditorium

Speakers Presentation Centre

Lift

Backstage

ChangeRoom

GreenRoom

ArbourSpeakers Lounge

Lobby

Arbour Boardroom

Lift

Lift

Arbour Foyer

Lift

BarArbour LoungeA2

Lift

Retail Mezzanine A1

Arbour Level Rooms Theatre Classroom Banquet Cocktail Metres2

Arbour Lounge - - - 150 190

Meeting Room A1 50 30 20 60 70

Meeting Room A2 120 70 80 120 120

Arbour Speakers Presentation Centre - - - - 70

Arbour Boardroom - - 16 - 38

Grey StMerivale St

Glenelg St

Melbourne StMezzanine Level

Foyer Level Ground Level

Arbour Level

Boulevard Level

Plaza Level(Grey Street)

(Grey Street)

(Grey Street)

(Grey Street)

(Grey Street)

Sky Level(Grey Street)

Plaza Level(Merivale Street)

(Merivale Street)

(Merivale Street)

Concord Level

Important notes• Theatre and classroom capacities include staging, for speaker appropriate to the size of the room.• Banquet and cocktail capacities are the comfortable maximums for each room. Staging and/or dance floors have not been incorporated and will reduce these capacities.• Information accurate at time of printing.

more personal - more choice

31.7.2012 www.bcec.com.au

Arbour Level

Sponsor Floor Plan

Merck Sharp and Dohme 10

Astrazeneca 9

Roche 4

Bristol Myers Squibb 8

Pfizer 11

Amgen 12

Merck 1

Ipsen 2

Astellas 3

Teva 5

Novartis 6

Janssen 7

Cancer Council Queensland 13

Pierre Fabre 14

Seqirus 15

Aspen 16

Mundipharma 17

Essen/Abacus 18

Agena Bioscience 19

B1B2B3

BOULEVARD AUDITORIUM FOYER

REGI

STRA

TION

UP

UP

UP

14 13

7654321

891011121516171819

Merck

Merck Sharp and Dohme

Ipsen Astellas

Pierre Fabre

Cancer Council of

Queensland

AspenEssen/Abacus

Agena Bioscience

Mundipharma Seqirus

Roche Teva Novartis Janssen

AstrazenecaPfizerAmgenBristol Myers

Squibb

Thursday, 24 November – Friday 25 November 2016Brisbane Convention and Exhibition Centre

Brisbane Cancer Conference